Newsfile Corp
14 Aug 2026, 19:43 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
The FDA stated that the benefit-risk profile for Capricor's lead product candidate, Deramiocel, looked unfavorable due to a lack of evidence supporting its effectiveness. — Direct negative feedback from the FDA on a lead product candidate significantly increases the risk of BLA rejection and destroys the primary value driver for a biotech firm.
-0.90The FDA considers Capricor's analyses for Deramiocel to be post-hoc and exploratory because the company changed its statistical analysis plan without FDA agreement just one day before unblinding data. — Allegations of improper data analysis and lack of scientific justification undermine the credibility of the company's clinical results.
-0.70A class action securities lawsuit has been filed against Capricor Therapeutics alleging the company failed to disclose material information during the class period. — While secondary to the FDA's findings, legal action creates additional financial liability and suggests governance failures.
-0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company is facing a class action lawsuit and unfavorable FDA feedback regarding its lead product candidate.
The company is facing a securities fraud class action due to undisclosed regulatory compliance failures and a 32% stock decline.
The company is facing a securities fraud class action following erroneous financial statements and a 31% stock decline.
The company is facing a securities fraud class action related to deceptive interest payments.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
59m ago
